Cencora FKA Amerisourcebergen Corporation
Pharmaceutical Services
Based in PA
🤖
AI Overview
With $1.6M in lobbying spend across 32 quarterly filings, Cencora FKA Amerisourcebergen Corporation is a significant lobbying presence. Their lobbying covers 1 issue area. Active from 2018 to 2025.
$1.6M
Total Spend
8
Years Active
1
Firms Hired
3
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $200K |
| 2020 | $200K |
| 2021 | $200K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $200K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
- •Prompt Pay, ASP, Medicare Part B Issues, Medicare Access and CHIP Re authorization Act (MACRA)implementation, Drug Quality and Security Act Implementation, Direct fees
- •Prompt Pay, ASP, Medicare Part B Issues, Medicare Access and CHIP Re authorization Act (MACRA)implementation, Drug Quality and Security Act Implementation, Direct and indirect remuneration - drug pric
- •Prompt Pay; ASP; Medicare Part B Issues; Medicare Access and CHIP Re authorization Act (MACRA)implementation; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration - Drug Pric
- •Prompt Pay; ASP; Medicare Part B Issues; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration - Drug Pricing
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.